Stocktoria
REGENXBIO Inc. RGNX
REGENXBIO Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M | $10.4M | $4.6M |
| R&D expense | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M | $166.3M | $124.2M | $83.9M | $57.2M | $45.5M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M | -$119.2M | -$149.0M | $88.1M | -$75.9M | -$65.3M |
| Interest expense | — | — | $6.9M | $23.3M | $26.3M | $771,000 | — | — | — | — |
| Income tax | $0 | $0 | -$152,000 | -$84,000 | $13.4M | $5.2M | -$2.8M | $4.2M | $0 | -$435,000 |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M | -$111.2M | -$94.7M | $99.9M | -$73.2M | -$63.0M |
| EPS (diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M | -$54.1M | -$107.7M | $104.6M | -$58.0M | -$48.6M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M | $134.7M | -$80.9M | -$119.4M | $91.4M | -$65.2M | -$56.7M |
| Cash & equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M | $338.4M | $69.5M | $75.6M | $46.7M | $24.8M |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.1B | $708.2M | $497.9M | $543.8M | $198.7M | $172.7M |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M | $330.4M | $47.7M | $35.0M | $15.6M | $11.0M |
| Shareholders' equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M | $377.8M | $450.2M | $508.8M | $183.0M | $161.7M |
Growth · year-over-year · Revenue CAGR 49.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +104.5% | -7.7% | -19.9% | -76.0% | +204.3% | +338.7% | -83.9% | +2002.4% | +126.5% | -39.5% |
| Net income growth | — | — | — | -319.3% | — | — | -194.8% | — | — | — |
| EPS growth | — | — | — | -323.4% | — | — | -194.5% | — | — | — |
| Free cash flow growth | — | — | — | -276.8% | — | — | -230.7% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.